Information Provided By:
Fly News Breaks for January 17, 2017
ADHD
Jan 17, 2017 | 11:14 EDT
Roth Capital analyst Michael Higgins downgraded Alcobra to Neutral from Buy after the company announced that the partially-enrolled Phase 3 MEASURE trial failed to meet primary endpoint. The analyst also lowered his price target on the shares to $1 from $7.50.
News For ADHD From the Last 2 Days
There are no results for your query ADHD